We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





GK Pharmaceuticals Accu-Right SARS-CoV-2 RT-PCR Kit Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 23 Sep 2020
Print article
Illustration
Illustration
GK Pharmaceuticals CMO (Manatí, Puerto Rico, USA) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the company’s GK ACCU-RIGHT SARS-CoV-2 assay.

The GK ACCU-RIGHT SARS-CoV-2 assay is an in vitro diagnostic RT-PCR test intended for the qualitative detection of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in upper respiratory specimens (such as nasopharyngeal, oropharyngeal, midturbinate, and nasal swabs) collected from individuals suspected of COVID-19 by their healthcare provider. The assay utilizes primers and probes targeting RNA from the virus nucleocapsid phosphoprotein (N) gene of the SARS-CoV-2 coronavirus. Testing consists of nucleic acid extraction followed by RT-PCR.

The GK ACCU-RIGHT SARS-CoV-2 RT-PCR KIT utilizes primers and probes targeting RNA from the SARS-CoV-2 coronavirus N gene. The panel is designed for specific detection of two unique regions (N1 and N2) of the SARS-CoV-2 (two primer/probe sets). The primer and probe sets are based on the US Centers for Disease Control and Prevention (US CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel. An additional primer/probe set to detect the human RNase P gene (RP) in control samples and clinical specimens is also included in the panel. The internal control RP will serve as an endogenous nucleic acid extraction control present in all properly collected patient simples and serves as both an extraction control and an internal amplification control. All three targets are amplified in individual reactions.

RNA isolated from upper respiratory specimens is reverse transcribed to cDNA and subsequently amplified using Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument with SDS software version 1.4. During the amplification process, the probe anneals to a specific target sequence located between the forward and reverse primers. During the extension phase of the PCR cycle, the 5’ nuclease activity of Taq polymerase degrades the bound probe, causing the reporter dye (FAM) to separate from the quencher dye (BHQ), generating a fluorescent signal. Fluorescence intensity is monitored at each PCR cycle by Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.

Related Links:
GK Pharmaceuticals CMO


Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.